Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Current status of topical antiretroviral chemoprophylaxis

Current status of topical antiretroviral chemoprophylaxis REVIEW URRENT Current status of topical antiretroviral PINION chemoprophylaxis Lut Van Damme and Michael Szpir Purpose of review Recent studies suggest that the vaginal delivery of antiretroviral (ARV) agents — such as tenofovir, dapivirine and UC781 — may be a promising way to reduce the high rates of HIV infection among women in developing countries. This review examines these developments. Recent findings The Microbicide Trials Network 003 study, a large phase IIb trial, was unable to show that daily dosing with 1% tenofovir vaginal gel was effective for HIV prevention. Nevertheless, preclinical and early-phase clinical trials suggest that ARV drugs — formulated in vaginal gels, rings, films, tablets and diaphragms — could be effective for HIV chemoprophylaxis. Summary Investigations of topical chemoprophylaxis methods have seen mixed results in the past 12–18 months. Product adherence may prove to be one of the field’s greatest challenges. Phase II and III trials continue to explore different dosing strategies for topical products that contain one or more ARV agents. Keywords antiretrovirals, clinical trials, HIV, microbicides, topical preexposure prophylaxis INTRODUCTION ANTIRETROVIRAL CANDIDATES FOR TOPICAL CHEMOPROPHYLAXIS The Centre for the AIDS Programme of Research && in South Africa (CAPRISA) 004 trial [1 ] was a http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Current status of topical antiretroviral chemoprophylaxis

Szpir, Michael
Current Opinion in HIV and Aids , Volume 7 (6) – Nov 1, 2012
Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/current-status-of-topical-antiretroviral-chemoprophylaxis-0GuTi1Sfoz

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0b013e3283582ca7
pmid
22918449
Publisher site
See Article on Publisher Site

Abstract

REVIEW URRENT Current status of topical antiretroviral PINION chemoprophylaxis Lut Van Damme and Michael Szpir Purpose of review Recent studies suggest that the vaginal delivery of antiretroviral (ARV) agents — such as tenofovir, dapivirine and UC781 — may be a promising way to reduce the high rates of HIV infection among women in developing countries. This review examines these developments. Recent findings The Microbicide Trials Network 003 study, a large phase IIb trial, was unable to show that daily dosing with 1% tenofovir vaginal gel was effective for HIV prevention. Nevertheless, preclinical and early-phase clinical trials suggest that ARV drugs — formulated in vaginal gels, rings, films, tablets and diaphragms — could be effective for HIV chemoprophylaxis. Summary Investigations of topical chemoprophylaxis methods have seen mixed results in the past 12–18 months. Product adherence may prove to be one of the field’s greatest challenges. Phase II and III trials continue to explore different dosing strategies for topical products that contain one or more ARV agents. Keywords antiretrovirals, clinical trials, HIV, microbicides, topical preexposure prophylaxis INTRODUCTION ANTIRETROVIRAL CANDIDATES FOR TOPICAL CHEMOPROPHYLAXIS The Centre for the AIDS Programme of Research && in South Africa (CAPRISA) 004 trial [1 ] was a

Journal

Current Opinion in HIV and Aids – Wolters Kluwer Health

Published: Nov 1, 2012

There are no references for this article.